XML 23 R14.htm IDEA: XBRL DOCUMENT
v3.25.1

Net Income Per Common Share | 3 Months Ended
--- | ---
Mar. 31, 2025
Earnings Per Share [Abstract] |
Net Income Per Common Share | (4) N ET INCOME PER COMMON SHARE The following sets forth a reconciliation of net income to basic net income attributable to common shareholders to diluted net income attributable to common shareholders (in thousands, except per share amounts):
| Three Months Ended March 31, |
| 2025 |  |  | 2024 |
Net income, as reported | $ | 97,052 |  |  | $ | 92,138 |
Participating earnings (a) |  | (299 | ) |  |  | (600 | )
Basic net income attributed to common shareholders |  | 96,753 |  |  |  | 91,538 |
Reallocation of participating earnings (a) |  | 2 |  |  |  | 4 |
Diluted net income attributed to common shareholders | $ | 96,755 |  |  | $ | 91,542 |
Net income per common share: |  |  |  |  |
Basic | $ | 0.40 |  |  | $ | 0.38 |
Diluted | $ | 0.40 |  |  | $ | 0.38 |
(a) Restricted Stock Liability Awards (discussed in Note 9) represent participating securities because they participate in non-forfeitable dividends or distributions with common equity owners. Income allocable to participating securities represents the distributed and undistributed earnings attributable to the participating securities. Participating securities, however, do not participate in undistributed net losses. The following details weighted average common shares outstanding and diluted weighted average common shares outstanding (in thousands):
| Three Months Ended March 31, |
| 2025 |  |  | 2024 |
Weighted average common shares outstanding – basic |  | 240,035 |  |  |  | 240,505 |
Effect of dilutive securities: |  |  |  |  |
Director and employee restricted stock and performance-based equity awards |  | 1,720 |  |  |  | 1,901 |
Weighted average common shares outstanding – diluted |  | 241,755 |  |  |  | 242,406 |
Weighted average common shares outstanding – basic for first quarter 2025 exclu des 741,000 s hares of restricted stock held in our deferred compensation plan compared to 1.6 million shares in first quarter 2024 (although all awards are issued and outstanding upon grant). For the three months ended March 31, 2025, equity grants of 245,000 sh ares compared to 127,000 shares in the same period of the prior year were outstanding but not included in the computation of diluted net income because the grant prices were greater than the average market price of the common shares and would be anti-dilutive to the computation.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration